Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
C4AdgwkZKWFpAwSL